Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged >= 65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy

DeAngelo, Daniel J., Sekeres, Mikkael A., Ottmann, Oliver, Sanz, Miguel A., Naoe, Tomoki, Taube, Tillmann, Belsack, Valerie, Ge, Miaomiao and Doehner, Hartmut 2015. Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged >= 65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy. Clinical Lymphoma, Myeloma and Leukemia 15 , S194-S194. 10.1016/j.clml.2015.04.046

Full text not available from this repository.
Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
Publisher: Elsevier
ISSN: 2152-2650
Last Modified: 04 Jun 2017 09:33
URI: http://orca-mwe.cf.ac.uk/id/eprint/96773

Actions (repository staff only)

Edit Item Edit Item